城市24小时 | 科创板再度“扩容”，哪座城市有望“抢跑”

Group 1 - The core point of the news is the upcoming IPO of He Yuan Biotechnology, which will be the first company to utilize the newly reintroduced fifth listing standard on the Sci-Tech Innovation Board [1][2] - He Yuan Biotechnology plans to raise 2.4 billion yuan for the construction of a human albumin industrialization base, new drug research and development projects, and to supplement working capital [1] - The company, established in 2006, primarily engages in innovative drug research and development, with current revenues mainly from non-core products such as pharmaceutical excipients and research reagents, and has not yet achieved profitability [1][2] Group 2 - The fifth listing standard is designed for companies with complex product technologies, significant capital investment, and long research and development cycles, and will now also support enterprises in artificial intelligence, commercial aerospace, and low-altitude economy [2] - Since the establishment of the Sci-Tech Innovation Board, 588 listed companies have a total market value exceeding 6.8 trillion yuan, with cumulative fundraising surpassing 1 trillion yuan, significantly supporting the development of new productive forces [2] - In 2024, the 54 unprofitable companies listed on the Sci-Tech Innovation Board achieved a total revenue of 174.48 billion yuan, with 26 companies exceeding 1 billion yuan in revenue [2] Group 3 - The new round of reforms aims to deepen the comprehensive reform of capital market investment and financing, better serving technological innovation and the development of new productive forces [3] - The distribution of the 588 listed companies spans 23 provinces, with Jiangsu having the strongest presence at 114 companies, followed by Shanghai and Guangdong [3][8] - The "Yangtze River Delta" region shows a strong performance, with six out of the top ten cities for listed companies located there [7][8]